3/18
06:13 am
idya
IDEAYA Biosciences Announces Upcoming Presentations at AACR 2026 Highlighting Multiple Clinical Stage Pipeline Programs [Yahoo! Finance]
Medium
Report
IDEAYA Biosciences Announces Upcoming Presentations at AACR 2026 Highlighting Multiple Clinical Stage Pipeline Programs [Yahoo! Finance]
3/18
06:00 am
idya
IDEAYA Biosciences Announces Upcoming Presentations at AACR 2026 Highlighting Multiple Clinical Stage Pipeline Programs
Medium
Report
IDEAYA Biosciences Announces Upcoming Presentations at AACR 2026 Highlighting Multiple Clinical Stage Pipeline Programs
3/9
06:22 am
idya
IDEAYA Biosciences Announces First-Patient-In for Phase 1 Trial of IDE892, a Potential Best-In-Class PRMT5 Inhibitor for MTAP-Deleted Solid Tumors, and Provides MTAP and CDKN2A Pipeline Update [Yahoo! Finance]
Medium
Report
IDEAYA Biosciences Announces First-Patient-In for Phase 1 Trial of IDE892, a Potential Best-In-Class PRMT5 Inhibitor for MTAP-Deleted Solid Tumors, and Provides MTAP and CDKN2A Pipeline Update [Yahoo! Finance]
3/9
06:00 am
idya
IDEAYA Biosciences Announces First-Patient-In for Phase 1 Trial of IDE892, a Potential Best-In-Class PRMT5 Inhibitor for MTAP-Deleted Solid Tumors, and Provides MTAP and CDKN2A Pipeline Update
Low
Report
IDEAYA Biosciences Announces First-Patient-In for Phase 1 Trial of IDE892, a Potential Best-In-Class PRMT5 Inhibitor for MTAP-Deleted Solid Tumors, and Provides MTAP and CDKN2A Pipeline Update
3/6
10:36 am
idya
IDEAYA Biosciences, Inc. (IDYA) Enrolls First Patient in Phase 1 Trial of IDE034 Bispecific ADC [Yahoo! Finance]
Low
Report
IDEAYA Biosciences, Inc. (IDYA) Enrolls First Patient in Phase 1 Trial of IDE034 Bispecific ADC [Yahoo! Finance]
2/27
07:19 pm
idya
Biocytogen Announces Clinical Milestone with First Patient Dosed in Phase 1 Trial of IDEAYA's First-in-Class B7H3/PTK7 Bispecific TOP1 ADC IDE034 [Yahoo! Finance]
Low
Report
Biocytogen Announces Clinical Milestone with First Patient Dosed in Phase 1 Trial of IDEAYA's First-in-Class B7H3/PTK7 Bispecific TOP1 ADC IDE034 [Yahoo! Finance]
2/27
07:00 pm
idya
Biocytogen Announces Clinical Milestone with First Patient Dosed in Phase 1 Trial of IDEAYA’s First-in-Class B7H3/PTK7 Bispecific TOP1 ADC IDE034
Low
Report
Biocytogen Announces Clinical Milestone with First Patient Dosed in Phase 1 Trial of IDEAYA’s First-in-Class B7H3/PTK7 Bispecific TOP1 ADC IDE034
2/27
07:00 pm
idya
Biocytogen Announces Clinical Milestone with First Patient Dosed in Phase 1 Trial of IDEAYA’s First-in-Class B7H3/PTK7 Bispecific TOP1 ADC IDE034
Low
Report
Biocytogen Announces Clinical Milestone with First Patient Dosed in Phase 1 Trial of IDEAYA’s First-in-Class B7H3/PTK7 Bispecific TOP1 ADC IDE034
2/27
06:00 am
idya
IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
Low
Report
IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
2/25
06:00 am
idya
IDEAYA Biosciences Announces First-Patient-In for Phase 1 Trial of IDE034, a Potential First-In-Class B7H3/PTK7 Bispecific TOP1 ADC
Low
Report
IDEAYA Biosciences Announces First-Patient-In for Phase 1 Trial of IDE034, a Potential First-In-Class B7H3/PTK7 Bispecific TOP1 ADC
2/23
06:00 am
idya
IDEAYA Biosciences Announces Appointment of Dr. Theodora (Theo) Ross, M.D., Ph.D., as Chief Development Officer
Low
Report
IDEAYA Biosciences Announces Appointment of Dr. Theodora (Theo) Ross, M.D., Ph.D., as Chief Development Officer
2/19
07:20 am
idya
IDEAYA Biosciences (NASDAQ:IDYA) had its "buy" rating reaffirmed by analysts at Citigroup Inc..
Medium
Report
IDEAYA Biosciences (NASDAQ:IDYA) had its "buy" rating reaffirmed by analysts at Citigroup Inc..
2/18
11:37 am
idya
IDEAYA Biosciences (NASDAQ:IDYA) had its "outperform" rating reaffirmed by analysts at Royal Bank Of Canada. They now have a $49.00 price target on the stock.
Low
Report
IDEAYA Biosciences (NASDAQ:IDYA) had its "outperform" rating reaffirmed by analysts at Royal Bank Of Canada. They now have a $49.00 price target on the stock.
2/18
11:15 am
idya
IDEAYA Biosciences (NASDAQ:IDYA) had its "overweight" rating reaffirmed by analysts at Cantor Fitzgerald.
Low
Report
IDEAYA Biosciences (NASDAQ:IDYA) had its "overweight" rating reaffirmed by analysts at Cantor Fitzgerald.
2/18
10:42 am
idya
IDEAYA Biosciences (NASDAQ:IDYA) had its "buy" rating reaffirmed by analysts at Guggenheim. They now have a $50.00 price target on the stock.
Low
Report
IDEAYA Biosciences (NASDAQ:IDYA) had its "buy" rating reaffirmed by analysts at Guggenheim. They now have a $50.00 price target on the stock.
2/18
08:42 am
idya
IDEAYA Biosciences (NASDAQ:IDYA) had its price target raised by analysts at Wedbush from $49.00 to $52.00. They now have an "outperform" rating on the stock.
Medium
Report
IDEAYA Biosciences (NASDAQ:IDYA) had its price target raised by analysts at Wedbush from $49.00 to $52.00. They now have an "outperform" rating on the stock.
2/17
06:00 am
idya
IDEAYA Biosciences Reports Fourth Quarter and Full Year 2025 Financial Results and Provides a Business Update
Low
Report
IDEAYA Biosciences Reports Fourth Quarter and Full Year 2025 Financial Results and Provides a Business Update
2/2
02:31 pm
idya
Has The Market Overreacted To Recent Weakness In IDEAYA Biosciences (IDYA) Shares? [Yahoo! Finance]
Low
Report
Has The Market Overreacted To Recent Weakness In IDEAYA Biosciences (IDYA) Shares? [Yahoo! Finance]
2/2
06:26 am
idya
IDEAYA Biosciences to Participate in Upcoming February 2026 Investor Relations Events [Yahoo! Finance]
Medium
Report
IDEAYA Biosciences to Participate in Upcoming February 2026 Investor Relations Events [Yahoo! Finance]
2/2
06:00 am
idya
IDEAYA Biosciences to Participate in Upcoming February 2026 Investor Relations Events
Medium
Report
IDEAYA Biosciences to Participate in Upcoming February 2026 Investor Relations Events
2/2
12:20 am
idya
A Look At IDEAYA Biosciences (IDYA) Valuation After Recent Share Price Pullback [Yahoo! Finance]
Medium
Report
A Look At IDEAYA Biosciences (IDYA) Valuation After Recent Share Price Pullback [Yahoo! Finance]
1/30
06:00 am
idya
IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
Low
Report
IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
1/24
05:08 am
idya
IDEAYA Biosciences (NASDAQ:IDYA) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.
Low
Report
IDEAYA Biosciences (NASDAQ:IDYA) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.
1/21
07:17 am
idya
IDEAYA Biosciences (NASDAQ:IDYA) had its "outperform" rating reaffirmed by analysts at Royal Bank Of Canada.
Low
Report
IDEAYA Biosciences (NASDAQ:IDYA) had its "outperform" rating reaffirmed by analysts at Royal Bank Of Canada.
1/11
01:27 pm
idya
IDEAYA Biosciences Provides a Business Update and Outlines 2026 Corporate Objectives at the 44th Annual J.P. Morgan Healthcare Conference [Yahoo! Finance]
Low
Report
IDEAYA Biosciences Provides a Business Update and Outlines 2026 Corporate Objectives at the 44th Annual J.P. Morgan Healthcare Conference [Yahoo! Finance]